Cirrhosis News and Research

Latest Cirrhosis News and Research

EMA COMP issues positive opinion to Albireo for A4250

Albireo AB, a biopharmaceutical company specializing in gastroenterology, today announced that the European Medicines Agency Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on an application for orphan medicinal product status for the company's lead hepatology candidate, A4250.

25 Jul 2012

Herbal therapy no alternative in HCV infection

The commonly used herbal remedy, silymarin, offers no benefit to patients with treatment-resistant hepatitis C virus infection, a study shows.

23 Jul 2012

WHO identifies key actions countries can take to prevent HIV infections among people who inject drugs

WHO has identified four key actions countries can take to prevent viral hepatitis B and C among people who inject drugs. Of the estimated 16 million people who inject drugs worldwide, it is estimated that 10 million are infected with hepatitis C. An additional 1.2 million are infected with hepatitis B.

21 Jul 2012

Antibody detects progenitor cells in cancers and cirrhosis of liver

The study, published in the journal Stem Cell, adds to our understanding of the role of stem and next stage progenitor cells in tissue regeneration and in the diagnosis and treatment of cancer.

21 Jul 2012

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor.

20 Jul 2012

HCV infections can lead to increased mortality from liver disease or variety of other causes

In a long-term study of people infected with the hepatitis C virus (HCV), researchers found increased deaths from both liver-related and non-liver related diseases in patients with active infections who had not cleared their infection.

19 Jul 2012

Silymarin does not provide greater benefit for patients with chronic HCV infection

Use of the botanical product silymarin, an extract of milk thistle that is commonly used by some patients with chronic liver disease, did not provide greater benefit than placebo for patients with treatment-resistant chronic hepatitis C virus (HCV) infection, according to a study in the July 18 issue of JAMA.

18 Jul 2012

Hepatitis C treatment may be helped by vitamin B12 supplements

Adding vitamin B12 to standard hepatitis C virus (HCV) treatment significantly boosts the body’s ability to keep the virus at bay, indicates a pilot study published online in the journal Gut.

18 Jul 2012

Smoking, hepatitis and liver transplantation: An interview with Dr Peter Ghali

We are very interested in hepatitis C as it is the most common indication for liver transplant in the Western world. The difficulty is that recurrence happens in the majority of patients within the first 2 to 7 years after transplant, and occasionally sooner.

18 Jul 2012

InvivoSciences, WUSTL to construct artificial tissue models for heart failure

The National Institutes of Health has awarded more than $2 million to a team of scientists from Washington University in St. Louis and InvivoSciences, a biotechnology startup with WUSTL roots, to construct artificial tissue models that will allow the rapid testing of new drugs for heart failure.

17 Jul 2012

Liver failure, cancer and mortality in cirrhotic patients coinfected with HIV/AIDS and HCV predicted by liver stiffness

Researchers from Spain established that liver stiffness, measured by transient elastography (TE), is an independent predictor of liver failure, hepatocellular carcinoma (HCC), and mortality in cirrhotic patients coinfected with the human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS), and hepatitis C virus (HCV).

10 Jul 2012

Scientists develop new animal model to study nonalcoholic steatohepatitis

Scientists at Texas Biomed have developed the laboratory opossum as a new animal model to study the most common liver disease in the nation - afflicting up to 15 million Americans - and for which there is no cure.

4 Jul 2012

DKK1 boosts liver cancer diagnostic options

Measurement of the protein Dickkopf-1 in serum could be used to diagnose hepatocellular carcinoma, especially early disease, Chinese researchers report.

2 Jul 2012

IU gastroenterologist develops first guidelines for diagnosis and management of NAFLD

An Indiana University School of Medicine gastroenterologist led a team of distinguished physicians who developed the first guidelines for diagnosis and management of non-alcoholic fatty liver disease.

22 Jun 2012

HCV suppression reduces liver damage

Profound suppression of the hepatitis C virus reduces long-term hepatic inflammation and fibrosis even in patients who do not achieve a sustained virologic response, research demonstrates.

19 Jun 2012

Hepatitis C more prevalent among homeless adults in downtown Los Angeles

Recent government studies show that hepatitis C, which can destroy the liver and necessitate a liver transplant, now kills more American adults than AIDS, and new UCLA research shows just how prevalent the disease is among homeless adults in downtown Los Angeles.

12 Jun 2012

Familial predisposition ‘modestly’ affects alcoholic liver disease risk

Environmental factors appear to be the main influence on the risk for alcoholic liver disease, say researchers who found little evidence for familial predisposition to the condition.

11 Jun 2012

Study identifies molecular changes responsible for abnormal cholesterol production and metabolism

A new study from the Virginia Commonwealth University School of Medicine has identified molecular changes responsible for abnormal cholesterol production and metabolism in the livers of patients with a common liver condition, and these changes may explain the severity of a patient's liver disease and risks to their heart health.

8 Jun 2012

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced final results from a randomized, placebo-controlled, double-blind, phase 2 clinical trial with the selective MET inhibitor tivantinib as a single-agent, investigational, second-line treatment in hepatocellular carcinoma (HCC).

4 Jun 2012

Foreign-born populations in the U.S. are at increased risk for chronic HBV

The prevalence of chronic hepatitis B virus (HBV) infection in the U.S. may be as high as 2.2 million cases according to a new study now available in Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

1 Jun 2012